Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients

NCT06897605 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Chronic Kidney Disease(CKD)
Anemia, Kidney Disease, Chronic

Interventions

DRUG: Dapagliflozin (DAPA)
DRUG: Erythropoiesis Stimulating Agent

Sponsor

Mansoura University